LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid Clinical Trial

Official title:

LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03049735
• Other study ID #: MVT-601-3001
• Secondary ID: 2016-003727-27
• Status: Completed
• Phase: Phase 3
• Start date: April 26, 2017
• Est. completion date: August 24, 2020

Study information

• Verified date: March 2022
• Source: Myovant Sciences GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.

Description:

This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral daily relugolix 40 mg co-administered with low-dose E2 and NETA (Group A) and 12 weeks of daily oral relugolix 40 mg alone followed by 12 weeks of daily oral relugolix 40 mg co-administered with low-dose E2 and NETA (Group B) compared with 24 weeks of placebo (Group C).

All participants completing the Week 24 visit, including women randomized to placebo, were offered the opportunity to enroll in an open-label extension study in which all eligible participants will receive relugolix co-administered with low-dose E2 and NETA. Participants who did not enroll into the extension study had a follow-up visit approximately 30 days after the end of treatment (that is, after the participant's last dose of study medication).

Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and assessments of bone mineral density.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 388
• Est. completion date: August 24, 2020
• Est. primary completion date: April 29, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Key Inclusion Criteria:

1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and dating the informed consent form.

2. Has regularly occurring menstrual periods of = 14 days duration with a cycle of 21 to 38 days from the start of 1 menstrual period until the start of the next, by participant history for at least 3 months prior to the first screening visit.

3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or transabdominal ultrasound performed during the screening period.

4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL of = 160 milliliter (mL) during 1 cycle or = 80 mL per cycle for 2 menstrual cycles as measured by the alkaline hematin method during the screening period.

Key Exclusion Criteria:

1. Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the patient's heavy menstrual bleeding.

2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine and proximal femur.

4. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the participant's bone mineral density is within normal limits.

5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss.

6. Has been a participant in an investigational drug or device study within the 1 month prior to the first screening visit.

Related Conditions & MeSH terms

• Heavy Menstrual Bleeding
• Hemorrhage
• Leiomyoma
• Menorrhagia
• Uterine Fibroid

Intervention

Drug:
• Relugolix
Relugolix (40 mg) tablet administered orally once daily.
• Estradiol/norethindrone acetate
E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
• Estradiol/norethindrone acetate placebo
E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
• Relugolix placebo
Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.

Locations

Country	Name	City	State
Brazil	Curitiba	Curitiba
Brazil	Porto Alegre	Porto Alegre
Brazil	Ribeirao Preto	Ribeirão Preto
Brazil	Santo Andre	Santo André
Brazil	Sao Paulo	São Paulo
Italy	Bologna	Bologna
Italy	Catanzaro	Catanzaro
Italy	Fiernze	Firenze
Italy	Genova	Genova
Italy	Milano	Milano
Italy	Modena	Modena
Italy	Monserrato	Monserrato
Italy	Napoli	Napoli
Italy	Roma	Roma
Italy	Roma	Roma
Italy	Siena	Siena
Italy	Torino	Torino
Poland	Katowice	Katowice
Poland	Lodz	Lódz
Poland	Lodz	Lódz
Poland	Lublin	Lublin
Poland	Lublin	Lublin
Poland	Poznan	Poznan
Poland	Szczecin	Szczecin
Poland	Warszawa	Warszawa
Poland	Warszawa	Warszawa
South Africa	Durban	Durban
South Africa	Durban	Durban
South Africa	Port Elizabeth	Port Elizabeth
South Africa	Roodepoort	Roodepoort
United Kingdom	Birmingham	Birmingham
United Kingdom	Isleworth	Isleworth
United Kingdom	London	London
United Kingdom	Nottingham	Nottingham
United States	Albuquerque	Albuquerque	New Mexico
United States	Andalusia	Andalusia	Alabama
United States	Atlanta	Atlanta	Georgia
United States	Atlanta	Atlanta	Georgia
United States	Augusta	Augusta	Georgia
United States	Aventura	Aventura	Florida
United States	Bismarck	Bismarck	North Dakota
United States	Bluffton	Bluffton	South Carolina
United States	Brandon	Brandon	Florida
United States	Charleston	Charleston	South Carolina
United States	Chattanooga	Chattanooga	Tennessee
United States	Cincinnati	Cincinnati	Ohio
United States	Cincinnati	Cincinnati	Ohio
United States	Clearwater	Clearwater	Florida
United States	Clermont	Clermont	Florida
United States	College Park	College Park	Georgia
United States	Columbia	Columbia	South Carolina
United States	Covington	Covington	Louisiana
United States	Dayton	Dayton	Ohio
United States	Denver	Denver	Colorado
United States	Durham	Durham	North Carolina
United States	Englewood	Englewood	Ohio
United States	Fargo	Fargo	North Dakota
United States	Fort Myers	Fort Myers	Florida
United States	Fort Worth	Fort Worth	Texas
United States	Greenville	Greenville	South Carolina
United States	Hialeah	Hialeah	Florida
United States	Hialeah	Hialeah	Florida
United States	Houston	Houston	Texas
United States	Houston	Houston	Texas
United States	Irving	Irving	Texas
United States	Jacksonville	Jacksonville	Florida
United States	La Mesa	La Mesa	California
United States	Lafayette	Lafayette	Indiana
United States	Las Vegas	Las Vegas	Nevada
United States	Las Vegas	Las Vegas	Nevada
United States	Lauderdale Lakes	Lauderdale Lakes	Florida
United States	Lawrenceville	Lawrenceville	New Jersey
United States	Lincoln	Lincoln	Nebraska
United States	Little Rock	Little Rock	Arkansas
United States	Lomita	Lomita	California
United States	Margate	Margate	Florida
United States	Memphis	Memphis	Tennessee
United States	Memphis	Memphis	Tennessee
United States	Miami	Miami	Florida
United States	Miami	Miami	Florida
United States	Miami	Miami	Florida
United States	Minot	Minot	North Dakota
United States	Mobile	Mobile	Alabama
United States	Morehead City	Morehead City	North Carolina
United States	Norfolk	Norfolk	Virginia
United States	Norwalk	Norwalk	California
United States	Oakbrook	Oakbrook Terrace	Illinois
United States	Oceanside	Oceanside	California
United States	Omaha	Omaha	Nebraska
United States	Orlando	Orlando	Florida
United States	Orlando	Orlando	Florida
United States	Palm Harbor	Palm Harbor	Florida
United States	Philadelphia	Philadelphia	Pennsylvania
United States	Raleigh	Raleigh	North Carolina
United States	Richland	Richland	Georgia
United States	St. Louis	Saint Louis	Missouri
United States	Salt Lake City	Salt Lake City	Utah
United States	Salt Lake City	Salt Lake City	Utah
United States	San Antonio	San Antonio	Texas
United States	San Diego	San Diego	California
United States	San Diego	San Diego	California
United States	Seattle	Seattle	Washington
United States	Shreveport	Shreveport	Louisiana
United States	South Miami	South Miami	Florida
United States	Sugar Land	Sugar Land	Texas
United States	Tampa	Tampa	Florida
United States	Webster	Webster	Texas
United States	West Palm Beach	West Palm Beach	Florida
United States	Weston	Weston	Florida
United States	Williamsville	Williamsville	New York

Sponsors (1)

Lead Sponsor	Collaborator
Myovant Sciences GmbH

Countries where clinical trial is conducted

United States,  Brazil,  Italy,  Poland,  South Africa,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A = 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA	A responder was a participant who had MBL volume of < 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 24). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 24/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented.; As per the objective of the study, the pre-specified primary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline up to last 35 days of treatment (up to Week 24)
Secondary	Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment	Amenorrhea was defined as meeting 1 of the following criteria for 2 consecutive visits: No feminine product returned due to reported amenorrhea; No feminine product returned due to reports of spotting/negligible bleeding coupled with electronic diary (eDiary) data indicating infrequent non-cyclic bleeding/spotting; Feminine product collection with a negligible observed MBL volume coupled with eDiary data indicating infrequent non-cyclic bleeding/spotting.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline up to last 35 days of treatment (up to Week 24)
Secondary	Percent Change From Baseline At Week 24 In MBL Volume	MBL volume was measured using the alkaline hematin method. As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Percentage Of Participants With A Hemoglobin Level = 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24	Blood samples were collected from participants for hemoglobin measurements. Percentages are based on number of participants with hemoglobin = 10.5 gram (g)/deciliter (dL) at Baseline and reported at Week 24.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA with placebo arms are presented.	From Baseline up to Week 24
Secondary	Percentage Of Participants With A Maximum NRS Score = 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment	Uterine fibroid-associated pain was assessed by a pain numerical rating scale (NRS). The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).; Participants were asked to document, in an e-Diary, the worst pain associated with their uterine fibroids that they experienced during the last 24 hours, every day until the end of study drug administration. Pain evaluable participants, defined as those who had maximum NRS score = 4 at Baseline and had at least 28 days (80% of the last 35 days of treatment) of pain scores recorded in the e-Diary, were analyzed.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline up to Week 24
Secondary	Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume	The volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Percent Change From Baseline At Week 24 In Uterine Volume	The volume of the uterus was measured by transvaginal or transabdominal ultrasound.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)	The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QoL) Bleeding and Pelvic Discomfort (BPD) Scale has been derived from the UFS-QoL Symptoms Scale. The scale consists of the following 3 symptoms proximal to uterine fibroids: Heavy bleeding during your menstrual period (Question [Q] 1), passing blood clots during your menstrual period (Q2), and feeling tightness or pressure in your pelvic area (Q5). raw scores were transformed to a normalized score: Transformed Score = [(Actual raw score - lowest possible raw score)/(Possible raw score range)] * 100 Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.; As per the study objective, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only these two arms are presented.	Baseline, Week 24
Secondary	Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 To L4), As Assessed By DXA	Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry (DXA) at the lumbar spine (L1, L2, L3, and L4) at Baseline and at Week 12. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD.; As per the objective of the study, the pre-specified secondary analyses compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below.	Baseline, Week 12
Secondary	Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck	BMD was assessed by DXA at the lumbar spine (L1, L2, L3, and L4), total hip, and femoral neck at Baseline and at Week 24. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12	An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term.; Reported CI based on exact binomial 95% CI (Clopper-Pearson).; As per the objective of the study, this secondary analysis compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12 and are presented below.	Baseline through Week 12
Secondary	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24	An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term.; Reported percentages based on the total number of participants in each treatment group.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline through Week 24
Secondary	Predose Trough Concentrations Of Relugolix And Norethindrone (NET) In The Relugolix Plus E2/NETA Group At Week 24	Blood samples for determination of relugolix and NET plasma concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.; Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics.; As per the objective of the study, only relugolix plus E2/NETA concentration is presented.	Week 24
Secondary	Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24	Blood samples for determination of E2 serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.; Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented.	Week 24
Secondary	Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group	Blood samples for determination of serum concentrations were collected predose at Week 24. Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.; Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics. As per the objective of the study, only relugolix plus E2/NETA concentration is presented.	Baseline, Week 24
Secondary	Time To MBL Response	Defined as the time to achieve an MBL volume of < 80 mL and a = 50% reduction from Baseline MBL volume as measured by the alkaline hematin method. MBL volume was measured using the alkaline hematin method.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Sustained Amenorrhea Rate (No Or Negligible Bleeding)	Sustained amenorrhea is defined as participants time to achieve and maintain amenorrhea until the date of last study drug.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Week 24
Secondary	Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)	Sustained amenorrhea status as determined based on time to achieve and maintain amenorrhea status.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Time To Achieving Amenorrhea (No Or Negligible Bleeding)	Time to amenorrhea was defined as the weeks from date of first dose of study drug to the start of amenorrhea.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Number Of Participants With Hemoglobin = 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Percent Change From Baseline In Hemoglobin For Women With a Hemoglobin = 10.5 g/dL At Baseline	LS means and p-value for test of difference is relugolix plus E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Week 24
Secondary	Number Of Participants With Hemoglobin Increase Of = 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Week 24
Secondary	Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score	Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score	Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score	Transformed score ranges from 0 to 100 based on Likert scale (none of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline In UFS-QoL Score By Health-Related Quality Of Life Total Score	The UFS-QoL total score was the sum of 6 subscales (concern, activities, energy/mood, control, self-conscious, and sexual function). The raw scores were transformed to normalized scores. Transformed score ranges from 0 to 100. Higher scores are indicative of better health-related quality of life (high = good).; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Change From Baseline In UFS-QoL Bleeding And Pelvic Discomfort Scale Score	The Bleeding and Pelvic Discomfort Scale consists of 3 items proximal to uterine fibroids that are experienced by most patients (heavy bleeding during the menstrual period [Question 1], passing blood clots during the menstrual period [Question 2], and feeling tightness or pressure in the pelvic area [Question 5]).Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Number Of Responders With At Least 20 Points Decrease In UFS-QoL Bleeding And Pelvic Discomfort Scale Score	A Responder was defined as meeting a meaningful change threshold, set as a 20-point change from Baseline, in the Bleeding And Pelvic Discomfort Scale at Week 24 on the transformed score.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11	Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20	Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29	Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity. A negative change from baseline indicates improvement.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire	The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire	The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]).; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Participants Achieving Improvement From Baseline In The PGA Questionnaire For Symptoms From Baseline At Week 24	The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at baseline to moderate.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Participants Achieving Improvement From Baseline In The PGA Questionnaire For Uterine Fibroid-related Function From Baseline At Week 24	The PGAs assessed participants' limitation in activities and the severity of symptoms due to uterine fibroids over the previous 4 weeks, as perceived by the participant. The PGA for function and symptoms was evaluated using a 5-point response scale (no limitation at all [1], mild limitation [2], moderate limitation [3], quite a bit of limitation [4], and extreme limitation [5]). Category improvements for symptoms are presented. A 1-category improvement would be severe at baseline to moderate.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline through Week 24
Secondary	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities	The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities	The Menorrhagia Impact was evaluated using a 5-point response scale to assess level of improvement from Baseline to Week 24. Response scale: Not at all, 2. Slightly, 3.Moderately, 4. Quite a bit and 5. Extremely.; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Number Of Participants Who Achieved A Maximum NRS Score = 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores = 4 During The 35 Days Prior To Randomization	Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	From Baseline up to the last 35 days of treatment (up to 24 weeks)
Secondary	Number Of Participants With A = 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores = 4 At Baseline	Uterine fibroid-associated pain was assessed by a pain NRS. The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain).; As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline In Luteinizing Serum Concentration At Week 24	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline In Follicle Stimulating Serum Concentration At Week 24	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline In E2 Serum Concentration At Week 24	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24
Secondary	Change From Baseline In Progesterone Serum Concentration At Week 24	As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.	Baseline, Week 24